Anti-Programmed death-ligand 1 (PD-L1) antibody/anti-programmed cell death -1 (PD-1) antibody can restore T cell function by blocking PD-1/PD-L1 signaling, and it is a novel anti-tumor immunotherapy regimen. This evidence concerns the gene CD274 and neoplasm.